Abstract
Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosourea (5 months versus 11.5 months). The combination of irinotecan and bevacizumab appeared to provide clinical benefit to patients with recurrent GB.
MeSH terms
-
Adult
-
Aged
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Brain Neoplasms / blood supply
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / mortality
-
Brain Neoplasms / therapy
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Carmustine / administration & dosage
-
Chemoradiotherapy / methods
-
Chemotherapy, Adjuvant / methods
-
Cohort Studies
-
Dacarbazine / administration & dosage
-
Dacarbazine / analogs & derivatives
-
Drug Therapy, Combination / methods
-
Glioblastoma / blood supply
-
Glioblastoma / drug therapy*
-
Glioblastoma / mortality
-
Glioblastoma / therapy
-
Humans
-
Irinotecan
-
Lomustine / administration & dosage
-
Middle Aged
-
Neoplasm Recurrence, Local / blood supply
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / mortality
-
Nitrosourea Compounds / therapeutic use*
-
Radiation-Sensitizing Agents / therapeutic use*
-
Retrospective Studies
-
Temozolomide
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Nitrosourea Compounds
-
Radiation-Sensitizing Agents
-
Bevacizumab
-
Irinotecan
-
Lomustine
-
Dacarbazine
-
Carmustine
-
Camptothecin
-
Temozolomide